BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 9883763)

  • 1. Bezafibrate and lovastatin decrease the oxidizability of low-density lipoproteins in heart transplant recipients with hyperlidemia.
    Zambrana JL; López-Miranda J; Blanco A; Arizón JM; Jansen S; Paniagua JA; Jimenéz-Perepérez JA; Concha M; Pérez-Jiménez F
    J Heart Lung Transplant; 1998 Dec; 17(12):1213-9. PubMed ID: 9883763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lovastatin versus bezafibrate for hyperlipemia treatment after heart transplantation.
    Hidalgo L; Zambrana JL; Blanco-Molina A; López-Granados A; Concha M; Casares J; Jiménez-Pérez J; López-Miranda J; Pérez-Jiménez F
    J Heart Lung Transplant; 1995; 14(3):461-7. PubMed ID: 7654731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A comparison of bezafibrate and lovastatin treatment at the usual doses in post-heart transplant hyperlipemia].
    Zambrana García JL; López Miranda J; Anguita Sánchez M; Blanco Cerrada J; Vallés Belsúe F; Casares Mediavilla J; Muñoz Carvajal I; Jiménez Perepérez JA; Pérez Jiménez F
    Rev Esp Cardiol; 1996 Dec; 49(12):892-8. PubMed ID: 9026840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of bezafibrate versus lovastatin for lowering plasma insulin, fibrinogen, and plasminogen activator inhibitor-1 concentrations in hyperlipemic heart transplant patients.
    Zambrana JL; Velasco F; Castro P; Concha M; Vallés F; Montilla P; Jimenéz-Perepérez JA; López-Miranda J; Pérez-Jiménez F
    Am J Cardiol; 1997 Oct; 80(7):836-40. PubMed ID: 9381994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response.
    Cenarro A; Artieda M; Gonzalvo C; Meriño-Ibarra E; Arístegui R; Gañán A; Díaz C; Sol JM; Pocoví M; Civeira F;
    Am Heart J; 2005 Dec; 150(6):1154-62. PubMed ID: 16338252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of severe, resistant familial combined hyperlipidemia with a bezafibrate-lovastatin combination.
    Yeshurun D; Abukarshin R; Elias N; Lanir A; Naschitz JE
    Clin Ther; 1993; 15(2):355-63. PubMed ID: 8519043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporine increases the oxidizability of low-density lipoproteins in renal transplant recipients.
    Apanay DC; Neylan JF; Ragab MS; Sgoutas DS
    Transplantation; 1994 Sep; 58(6):663-9. PubMed ID: 7524202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus.
    Castaño G; Menéndez R; Más R; Amor A; Fernández JL; González RL; Lezcay M; Alvarez E
    Int J Clin Pharmacol Res; 2002; 22(3-4):89-99. PubMed ID: 12837046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of bezafibrate on HDL2/HDL3 ratio in postmenopausal hypertriglyceridemic women.
    Ushiroyama T; Sakuma K; Nosaka S
    J Cardiovasc Pharmacol Ther; 2006 Jun; 11(2):142-8. PubMed ID: 16891292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies of LDL particle size and susceptibility to oxidation and association with glucose metabolism in children after heart transplantation.
    Siirtola A; Antikainen M; Ala-Houhala M; Solakivi T; Jokela H; Lehtimäki T; Holmberg C; Salo MK
    J Heart Lung Transplant; 2004 Apr; 23(4):418-26. PubMed ID: 15063401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-density lipoprotein oxidizability and the alteration of its fatty acid content in renal transplant recipients treated with cyclosporine/tacrolimus.
    Bakar F; Keven K; Dogru B; Aktan F; Erturk S; Tuzuner A; Erbay B; Nebioglu S
    Transplant Proc; 2009 Jun; 41(5):1630-3. PubMed ID: 19545695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
    Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
    Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.
    Manfredi R; Chiodo F
    J Infect; 2001 Apr; 42(3):181-8. PubMed ID: 11545549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin.
    Fujita N; Kaito M; Kai M; Sugimoto R; Tanaka H; Horiike S; Konishi M; Iwasa M; Watanabe S; Adachi Y
    J Viral Hepat; 2006 Jul; 13(7):441-8. PubMed ID: 16792537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluvastatin in combination with other lipid-lowering agents.
    Jokubaitis LA
    Br J Clin Pract Suppl; 1994 Dec; (77):28-32. PubMed ID: 19496270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of lovastatin and bezafibrate on cyclosporine-induced hyperlipidemia in rabbits.
    Hidalgo L; López-Miranda J; Espino A; Alcala J; Blanco J; Prada JL; Rodríguez M; Jiménez-Perepérez JA; Jansen S; Pérez-Jiménez F
    Transplant Proc; 1995 Apr; 27(2):1857-61. PubMed ID: 7725532
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of two lipid-lowering, carotenoid-controlled diets on the oxidative modification of low-density lipoproteins in free-living humans.
    Ahuja KD; Ashton EL; Ball MJ
    Clin Sci (Lond); 2003 Sep; 105(3):355-61. PubMed ID: 12780345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atherogenic risk reduction in patients with dyslipidaemia. comparison between bezafibrate and lovastatin.
    Sinzinger H; Pirich C; Kondor P; Etti H
    Eur Heart J; 1995 Nov; 16(11):1491-501. PubMed ID: 8881840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of calcineurin inhibitors on low-density lipoprotein oxidation.
    Cofan F; Cofan M; Campos B; Guerra R; Campistol JM; Oppenheimer F
    Transplant Proc; 2005 Nov; 37(9):3791-3. PubMed ID: 16386540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homocysteine elevation with fibrates: is it a class effect?
    Harats D; Yodfat O; Doolman R; Gavendo S; Marko D; Shaish A; Sela BA
    Isr Med Assoc J; 2001 Apr; 3(4):243-6. PubMed ID: 11344833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.